XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Schedule of Repurchase Agreements
The following table presents the Company’s Repurchase Program activity:
Total number of shares purchasedAverage price paid per shareApproximate value of shares purchased
Year Ended December 31, 2024
2,545,402 $11.79 $30,000 
Schedule of RSU Activity
The following table summarizes the Company’s RSU activity under the New Plan since December 31, 2024:
Number of RSUsWeighted-
average grant
date fair value
($)
Outstanding, December 31, 20241,293,970 9.69 
Granted1,176,475 13.22 
Vested and settled(460,620)9.53 
Forfeited, expired
(31,004)11.56 
Outstanding, March 31, 20251,978,821 11.80 
Schedule of Stock Options Granted
The following table summarizes the Company’s stock options granted in Canadian dollars under the Original Plan and the New Plan:
Number
of Options		Weighted-
Average
Exercise Price
(C$)		Weighted-
Average
Exercise Price
($)		Weighted-
Average
Contractual
Term
(years)		Aggregate
intrinsic value
(C$)		Aggregate
intrinsic value
($)
Outstanding, December 31, 20241,082,835 20.36 14.15 4.736,485 4,509 
Granted— — — 
Exercised(14,177)8.77 6.11 
Forfeited, expired
(3,266)24.31 16.90 
Outstanding, March 31, 20251,065,392 20.50 14.25 4.453,970 2,760 
The following table summarizes the Company’s stock options granted in U.S. dollars under the New Plan and the Inducement Plan:
Number
of Options		Weighted-
Average
Exercise Price
($)		Weighted-
Average
Contractual
Term
(years)		Aggregate
intrinsic value
($)
Outstanding, December 31, 20247,331,084 12.01 7.9730,459 
Granted1,551,225 13.18 
Exercised(70,686)8.28 
Forfeited(64,997)12.18 
Outstanding, March 31, 20258,746,626 12.25 8.0914,571 
Schedule of Stock-Based Compensation Expense for Equity Classified Instruments Stock-based compensation expense for equity classified instruments, RSUs, as well as the financial statement impact of the amortization and periodic revaluation of liability classified instruments, are recorded in research and development expense and general and administration expense as follows:
Three Months Ended March 31,
20252024
Research and development expense
$3,161 $1,925 
General and administrative expense
3,113 1,534 
Schedule of Estimated Fair Value of Stock Options Assumptions
The estimated fair value of stock options granted under the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions:
Three Months Ended March 31,
20252024
Dividend yield0 %0 %
Expected volatility63.1 %65.0 %
Risk-free interest rate4.58 %4.01 %
Expected average life of options6.06 years6.04 years
The weighted-average Black-Scholes option pricing assumptions for liability classified stock options outstanding at March 31, 2025 and 2024 are as follows:
Three Months Ended March 31,
20252024
Dividend yield
0 %0 %
Expected volatility
47.0 %49.1 %
Risk-free interest rate
2.30 %4.10 %
Expected average option term
0.63 years0.77 years
Number of liability classified stock options outstanding
272,330369,096